Who
Joshua Pinto
President & CEO
Company insider
Files Form 4 as: President & CEO, Neumora Therapeutics; Director, Metsera.
In numbers
- Trades disclosed
- 50
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $1.2M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 14 Feb 2024
- Last trade
- 20 Aug 2026
- Last filed
- 21 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 20 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $21K5,967 at $3.54 | filing |
| 17 Feb 2026filed 19 Feb 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $21K5,967 at $3.54 | filing |
| 8 Jan 2026filed 9 Jan 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,200,000 at $0.00 | filing |
| 8 Jan 2026filed 9 Jan 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,200,000 at $0.00 | filing |
| 13 Nov 2025filed 13 Nov 2025 | Metseraoption or derivative | SEC FORM 4 Code A | —2,688 | filing |
| 13 Nov 2025filed 13 Nov 2025 | Metseraoption or derivative | SEC FORM 4 Code D | —16,125 | filing |
| 13 Nov 2025filed 13 Nov 2025 | Metseraoption or derivative | SEC FORM 4 Code D | —148,953 | filing |
| 13 Nov 2025filed 13 Nov 2025 | Metsera | SEC FORM 4 Code D | —2,688 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —223,034 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —270,828 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —223,034 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —720,084 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —127,448 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —170,000 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,000,000 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —223,034 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —270,828 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —223,034 | filing |
News
No headline names them, or the companies they trade most, lately.